Navigation Links
Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention

WASHINGTON, D.C. (April 21, 2010)Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

"It appears that the investigational form of naproxen we studied may be more effective than standard naproxen in inhibiting colorectal tumor development," says Margie Clapper, Ph.D., Co-Leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center. "An added benefit would be the reduced gastrointestinal toxicity of this novel type of naproxen." Clapper's group will present the new data at the 2010 annual meeting of the American Association for Cancer Research.

"This new form of naproxen is probably more protective because it blocks one of the first steps in the colorectal cancer-causing pathway," she says.

Previous work from Clapper and others has shown that increased activity of the WNT/-catenin pathway is one of the earliest events in colorectal cancer formation. To test whether NO-naproxen could reduce activation of the pathway, the team used colon cancer cells that become bioluminescent when the WNT/-catenin pathway is active. They found that cells treated with NO-naproxen had about 50% less bioluminescence than cells treated with naproxen.

"The major and novel finding from the study is that the NO-naproxen can alter a particular signaling pathway that is one of the earliest events in colon cancer formation," Clapper says. "Based on the in vitro data, we think that NO-naproxen is much better than naproxen in nipping this whole process in the bud."

To confirm the in vitro results, the team has treated mice that are genetically predisposed to develop colorectal adenomas with NO-naproxen and naproxen and are awaiting the results of this study.

NSAIDs have been shown to reduce the risk of colon cancer and precancerous polyps in people. However, some of the agents have been taken off the market due to cardiovascular toxicity. With that in mind, Clapper says, "If we can find something in the same arena that is effective and nontoxic, it will be extremely valuable."

NO-naproxen and other NO-donating NSAID derivatives are a new class of agents being developed with the aim of reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.


Contact: Diana Quattrone
Fox Chase Cancer Center

Related medicine news :

1. Vitamin K may protect against developing non-Hodgkins lymphoma, say Mayo Clinic researchers
2. UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis
3. UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis
4. USC researchers discover new molecular subtype of brain cancer
5. Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers
6. Researchers find compound effective in destroying antibiotic-resistant biofilms
7. Boston researchers lead $15 million federal research grant to support advancement of health IT
8. Researchers discover new approach for identifying smokers at highest risk for developing lung cancer
9. Researchers aim for consensus on measuring the impact of visual impairment
10. Researchers Boost Post-Heart Attack Survival in Mice
11. Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: